Sources in the Indian vaccine companies have said whatever benefits are given to the foreign vaccine makers like Pfizer and Moderna should be given to them as well.
Appeal for Donations to the Corpus of Sameeksha Trust
This is an appeal to the subscribers, contributors, advertisers and well-wishers of Economic and Political Weekly (EPW), published by Sameeksha Trust, a public charitable trust registered with the office of the Charity Commissioner, Mumbai, India.
EXPLORE OUR FEATURES
The road ahead in India’s augmented vaccination drive
Updated:
Updated:
April 26, 2021 00:39 IST
Flattening the COVID-19 curve eventually rests on judicious vaccination deployment plans and the pace of vaccination
Share Article
AAA
Flattening the COVID-19 curve eventually rests on judicious vaccination deployment plans and the pace of vaccination
India is presently battling an aggressive second wave of the COVID-19 pandemic. India launched its vaccination drive in mid-January, starting with the vaccination of priority groups. The central government has announced a slew of policy measures to expand the eligibility bracket of vaccinees and to deploy more vaccines for domestic use. These policy interventions coupled with the availability of vaccines in the open market are expected to further intensify India’s anti-COVID-19 battle.
COMMENTS
The regulatory mechanism has been modified to save time in special situations like this pandemic Representational photo
Foreign-made vaccines will be able to able to bypass India’s infamous bureaucratic red tape and obtain import license and registration clearances in just three working days after being given emergency-use approval, said the Union health ministry on Thursday (April 15).
To accelerate the availability of vaccines in India witnessing a severe second surge in the pandemic, the government is pushing to fast-track the use of Covid-19 vaccines that are cleared by regulatory authorities in the US, the UK, the European Union, and Japan. A statement issued by the health ministry and reported by